HHC
AMPH icon

Hutchin Hill Capital’s Amphastar Pharmaceuticals AMPH Stock Holding History

Hutchin Hill Capital’s Portfolio AMPH Stock Details AMPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-73,100
Closed -$1.06M – 823
2017
Q1 		$1.06M Buy
+73,100
New +$1.15M 0.03% 474

Other funds holding AMPH

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TA
Teachers Advisors New York $81.7B AUM 13.62% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Hutchin Hill Capital's AMPH Position: Q2 2017 in Review

Hutchin Hill Capital sold out of Amphastar Pharmaceuticals (AMPH) in Q2 2017, closing a stake of 73,100 shares — an estimated $1.06M sold.

Hutchin Hill Capital first reported a position in AMPH in Q1 2017 and held it in 1 quarter. The position peaked at $1.06M in Q1 2017. 108 funds tracked by Wall St. Rank hold AMPH as of Q2 2017.

  • Hutchin Hill Capital reported no remaining Amphastar Pharmaceuticals position as of Q2 2017 after selling out during the quarter.
  • Hutchin Hill Capital sold 73,100 Amphastar Pharmaceuticals shares in Q2 2017, an estimated $1.06M.
  • Hutchin Hill Capital first reported a position in Amphastar Pharmaceuticals in Q1 2017 and held it in 1 quarter.
  • Hutchin Hill Capital's Amphastar Pharmaceuticals position peaked at $1.06M in Q1 2017.
  • 108 funds tracked by Wall St. Rank held Amphastar Pharmaceuticals as of Q2 2017.

Based on Hutchin Hill Capital's 13F filing for Q2 2017, filed 14 Aug 2017.